Second-line Drug Resistance Characterization in
Adolescent
Adult
Aged
Aged, 80 and over
Antitubercular Agents
/ therapeutic use
Child
Extensively Drug-Resistant Tuberculosis
/ drug therapy
Female
Genotype
Humans
India
/ epidemiology
Isoniazid
/ therapeutic use
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium tuberculosis
/ drug effects
Retrospective Studies
Rifampin
/ therapeutic use
Sensitivity and Specificity
Tuberculosis, Multidrug-Resistant
/ drug therapy
Young Adult
Drug resistance
MTBDRsl Ver 2.0
Mycobacterium tuberculosis
diagnosis
Journal
Journal of epidemiology and global health
ISSN: 2210-6014
Titre abrégé: J Epidemiol Glob Health
Pays: Switzerland
ID NLM: 101592084
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
22
04
2019
accepted:
03
12
2019
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
Tuberculosis (TB) remains a main hurdle for national programs due to increase in drug resistance to antitubercular drugs. World Health Organization (WHO)-endorsed Line Probe Assay, Genotype MTBDRsl Ver 2.0, gives opportunity for rapid diagnosis and molecular characterization of different mutations in drug targets of fluoroquinolone (FQ) and second-line injectable drugs (SLID). We, retrospectively, analyzed the data of Genotype MTBDRsl Ver 2.0 from January 2018 to June 2018. A total of 863 isolates of
Identifiants
pubmed: 32175709
pii: j10/1/42
doi: 10.2991/jegh.k.191215.003
pmc: PMC7310802
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-45Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2020 Atlantis Press International B.V.
Déclaration de conflit d'intérêts
The authors declare they have no conflicts of interest.
Références
Respirology. 2018 Jul;23(7):656-673
pubmed: 29641838
Indian J Med Res. 2016 Mar;143(3):341-7
pubmed: 27241648
Int J Tuberc Lung Dis. 2018 Apr 1;22(4):419-424
pubmed: 29562990
Int J Tuberc Lung Dis. 2010 Feb;14(2):243-6
pubmed: 20074419
Int J Infect Dis. 2014 Sep;26:149-53
pubmed: 25086437
Am J Public Health Nations Health. 1950 Oct;40(10):1305-10
pubmed: 14771316
PLoS One. 2018 Apr 11;13(4):e0193903
pubmed: 29641576
Cochrane Database Syst Rev. 2014 Oct 29;(10):CD010705
pubmed: 25353401
Indian J Tuberc. 2018 Jul;65(3):233-236
pubmed: 29933865
J Clin Microbiol. 2017 Mar;55(3):791-800
pubmed: 27974543
Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60
pubmed: 19723407
Tuberculosis (Edinb). 2012 Sep;92(5):404-6
pubmed: 22789499
J Infect. 2018 Oct;77(4):328-334
pubmed: 29969597